Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis

Autor: Dirk Woitalla, Ludger Schöls, Alfred Nordheim, Lena F. Burbulla, Doron Rapaport, Carola Schiesling, Olaf Riess, Thomas Illig, Peter Bauer, Stephan Jung, Manu Sharma, Hiroki Kato, Carina Schelling, Rejko Krüger, Claudia Schulte
Rok vydání: 2010
Předmět:
mortalin
Male
Mutant
metabolism [Parkinson Disease]
genetics [Membrane Potential
Mitochondrial]

Mitochondrion
Biology
metabolism [DNA Topoisomerases
Type II]

metabolism [Mitochondrial Proteins]
Mitochondrial Proteins
genetics [Molecular Chaperones]
genetics [HSP70 Heat-Shock Proteins]
genetics [Parkinson Disease]
ddc:570
Genetics
medicine
Humans
physiology [Mitochondria]
metabolism [Reactive Oxygen Species]
HSP70 Heat-Shock Proteins
Molecular Biology
Gene
Genetics (clinical)
Loss function
Aged
Membrane Potential
Mitochondrial

Gene knockdown
Neurodegeneration
Genetic Variation
Parkinson Disease
General Medicine
Articles
Middle Aged
medicine.disease
metabolism [Mitochondria]
Phenotype
Cell biology
Mitochondria
DNA-Binding Proteins
DNA Topoisomerases
Type II

Chaperone (protein)
Gene Knockdown Techniques
biology.protein
Female
physiopathology [Parkinson Disease]
metabolism [DNA-Binding Proteins]
Reactive Oxygen Species
Molecular Chaperones
Zdroj: Human molecular genetics 19(22), 4437-4452 (2010). doi:10.1093/hmg/ddq370
ISSN: 1460-2083
DOI: 10.1093/hmg/ddq370
Popis: The mitochondrial chaperone mortalin has been linked to neurodegeneration in Parkinson's disease (PD) based on reduced protein levels in affected brain regions of PD patients and its interaction with the PD-associated protein DJ-1. Recently, two amino acid exchanges in the ATPase domain (R126W) and the substrate-binding domain (P509S) of mortalin were identified in Spanish PD patients. Here, we identified a separate and novel variant (A476T) in the substrate-binding domain of mortalin in German PD patients. To define a potential role as a susceptibility factor in PD, we characterized the functions of all three variants in different cellular models. In vitro import assays revealed normal targeting of all mortalin variants. In neuronal and non-neuronal human cell lines, the disease-associated variants caused a mitochondrial phenotype of increased reactive oxygen species and reduced mitochondrial membrane potential, which were exacerbated upon proteolytic stress. These functional impairments correspond with characteristic alterations of the mitochondrial network in cells overexpressing mutant mortalin compared with wild-type (wt), which were confirmed in fibroblasts from a carrier of the A476T variant. In line with a loss of function hypothesis, knockdown of mortalin in human cells caused impaired mitochondrial function that was rescued by wt mortalin, but not by the variants. Our genetic and functional studies of novel disease-associated variants in the mortalin gene define a loss of mortalin function, which causes impaired mitochondrial function and dynamics. Our results support the role of this mitochondrial chaperone in neurodegeneration and underscore the concept of impaired mitochondrial protein quality control in PD.
Databáze: OpenAIRE